Salud financiera de hoja de balance de Milestone Pharmaceuticals
Salud financiera controles de criterios 5/6
Milestone Pharmaceuticals tiene un patrimonio de los accionistas total de $16.8M y una deuda total de $49.8M, lo que sitúa su ratio deuda-patrimonio en 296.8%. Sus activos y pasivos totales son $75.2M y $58.5M respectivamente.
Información clave
126.9%
Ratio deuda-patrimonio
US$50.64m
Deuda
| Ratio de cobertura de intereses | n/a |
| Efectivo | US$89.48m |
| Patrimonio | US$39.92m |
| Total pasivo | US$56.08m |
| Activos totales | US$96.00m |
Actualizaciones recientes sobre salud financiera
Is Milestone Pharmaceuticals (NASDAQ:MIST) A Risky Investment?
Sep 13
We're Keeping An Eye On Milestone Pharmaceuticals' (NASDAQ:MIST) Cash Burn Rate
Mar 07We're Keeping An Eye On Milestone Pharmaceuticals' (NASDAQ:MIST) Cash Burn Rate
Oct 15We Think Milestone Pharmaceuticals (NASDAQ:MIST) Can Afford To Drive Business Growth
Jun 24We're Hopeful That Milestone Pharmaceuticals (NASDAQ:MIST) Will Use Its Cash Wisely
Feb 25We're Interested To See How Milestone Pharmaceuticals (NASDAQ:MIST) Uses Its Cash Hoard To Grow
Aug 25Recent updates
Here's Why Shareholders Should Examine Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) CEO Compensation Package More Closely
Jun 07Is Milestone Pharmaceuticals (NASDAQ:MIST) A Risky Investment?
Sep 13We're Keeping An Eye On Milestone Pharmaceuticals' (NASDAQ:MIST) Cash Burn Rate
Mar 07We're Keeping An Eye On Milestone Pharmaceuticals' (NASDAQ:MIST) Cash Burn Rate
Oct 15We Think Milestone Pharmaceuticals (NASDAQ:MIST) Can Afford To Drive Business Growth
Jun 24We're Hopeful That Milestone Pharmaceuticals (NASDAQ:MIST) Will Use Its Cash Wisely
Feb 25We're Interested To See How Milestone Pharmaceuticals (NASDAQ:MIST) Uses Its Cash Hoard To Grow
Aug 25Companies Like Milestone Pharmaceuticals (NASDAQ:MIST) Are In A Position To Invest In Growth
Apr 02What You Need To Know About Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) Investor Composition
Jan 15First patient enrolled in Milestone Pharmaceuticals' late-stage study of etripamil in PSVT
Nov 18Milestone Pharmaceuticals EPS beats by $0.09
Nov 13Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo ($73.0M) de MIST superan a sus pasivos a corto plazo ($7.2M).
Pasivo a largo plazo: Los activos a corto plazo de MIST ($73.0M) superan a sus pasivos a largo plazo ($51.2M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: MIST tiene más efectivo que su deuda total.
Reducción de la deuda: El ratio deuda-patrimonio de MIST ha crecido de 0% a 296.8% en los últimos 5 años.
Hoja de balance
Análisis de cash runway
En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.
Cash runway estable: MIST tiene suficiente cash runway para más de un año basándose en su flujo de caja libre actual.
Pronóstico de cash runway: MIST dispone de suficiente cash runway para 1.4 años si el flujo de caja libre sigue reduciéndose a tasas históricas de 8.7% cada año.